Pharmacokinetics of Ampicillin in Neonates With Moderate to Severe Hypoxic-Ischemic Encephalopathy

Sponsor
Drexel University (Other)
Overall Status
Completed
CT.gov ID
NCT03129620
Collaborator
(none)
14
1
37
0.4

Study Details

Study Description

Brief Summary

Controlled Hypothermia has become the standard of care for neonates with moderate to severe HIE. Ampicillin and aminoglycosides are drugs that are universally used for the treatment of suspected neonatal sepsis, which may or may not be responsible for the etiology of HIE. Currently, medication dosage regimens are not altered in the setting of CH. A better understanding of the effects of our interventions on this unique population may help us tailor our therapy to the specific circumstances of the patient

Condition or Disease Intervention/Treatment Phase

    Detailed Description

    Hypoxic-ischemic encephalopathy (HIE) affects approximately 1 to 2 per 1000 live births and remains a cause of significant morbidity and mortality in the neonatal period. In response to an anoxic insult, perfusion to vital organs is preserved; however, when this injury is profound concomitant injury to nonvital organs is observed. Controlled hypothermia (CH) has been accepted as a neuroprotective therapeutic modality for neonates with moderate to severe HIE because of its role in attenuating secondary brain injury. Neonates exhibit varying degrees of multiorgan dysfunction after a hypoxic-ischemic insult, although the added beneficial and potential adverse effects that CH has in these babies have not been completely delineated or understood.

    CH has been shown to alter normal physiologic functioning of several organ systems. Specific physiologic changes as a consequence of CH have been demonstrated in both animal and human models. The observed reduction in cardiac output and reflexive increase in systemic vascular resistance in response to CH alter renal perfusion and subsequently reduce glomerular filtration . Drugs that are renally cleared may develop a prolonged half-life in this setting. Finally, drug metabolism may further be affected by altered hepatic blood flow and temperature-dependent effects on hepatic enzyme activity . Collectively, the potential effects of CH on drug metabolism and clearance are significant warranting further investigation. The investigator aims to evaluate the combined effects of hypoxia and hypothermia on ampicillin clearance and excretion

    Study Design

    Study Type:
    Observational
    Actual Enrollment :
    14 participants
    Observational Model:
    Case-Only
    Time Perspective:
    Prospective
    Official Title:
    Pharmacokinetics of Ampicillin in Neonates With Moderate to Severe Hypoxic-Ischemic Encephalopathy Undergoing Controlled Hypothermia
    Study Start Date :
    Mar 1, 2013
    Actual Primary Completion Date :
    Mar 1, 2016
    Actual Study Completion Date :
    Apr 1, 2016

    Outcome Measures

    Primary Outcome Measures

    1. Elevated ampicillin serum levels [3 years]

      Ampicillin concentration at 3 time points to determine clearance and serum levels

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    6 Hours to 24 Hours
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    No
    Inclusion Criteria:
    • Gestational age > 36 weeks

    • Birth weight > 1800 grams

    • Age < 6 hours old at the time of admission to the NICU

    • Cord gas or ABG/VBG with pH < 7.0 or base deficit > 16 within the first hour of life

    • Presence of seizures or evidence of moderate to severe encephalopathy

    • Presence of central line for lab draws

    Exclusion Criteria:

    • Infants admitted for CH without central intravascular access.

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 St Christopher's Hospital for children Philadelphia Pennsylvania United States 19134

    Sponsors and Collaborators

    • Drexel University

    Investigators

    None specified.

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    Ogechukwu Menkiti, md, Drexel University
    ClinicalTrials.gov Identifier:
    NCT03129620
    Other Study ID Numbers:
    • 1301001808
    First Posted:
    Apr 26, 2017
    Last Update Posted:
    Apr 26, 2017
    Last Verified:
    Apr 1, 2017
    Individual Participant Data (IPD) Sharing Statement:
    No
    Plan to Share IPD:
    No
    Keywords provided by Ogechukwu Menkiti, md, Drexel University
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of Apr 26, 2017